These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 4039117)

  • 1. Pharmacokinetics of aztreonam in patients with gram-negative infections.
    Janicke DM; Cafarell RF; Parker SW; Apicella MA; Jusko WJ
    Antimicrob Agents Chemother; 1985 Jan; 27(1):16-20. PubMed ID: 4039117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of aztreonam in infected patients.
    Mattie H; Matze-van der Lans A
    J Antimicrob Chemother; 1986 Feb; 17(2):215-9. PubMed ID: 3700287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction.
    Mihindu JC; Scheld WM; Bolton ND; Spyker DA; Swabb EA; Bolton WK
    Antimicrob Agents Chemother; 1983 Aug; 24(2):252-61. PubMed ID: 6685452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis.
    Winslade NE; Smith IL; Simons GW; Swanson DJ; Vigano A; Wels PB; Schentag JJ
    Rev Infect Dis; 1985; 7 Suppl 4():S716-23. PubMed ID: 3909329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of carumonam in patients with renal insufficiency.
    Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
    Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.
    Lee DH; Kim YK; Jin K; Kang MJ; Joo YD; Kim YW; Moon YS; Shin JG; Kiem S
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
    Gerig JS; Bolton ND; Swabb EA; Scheld WM; Bolton WK
    Kidney Int; 1984 Sep; 26(3):308-18. PubMed ID: 6542606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical trial of aztreonam and aminoglycoside antibiotics in the treatment of serious infections caused by gram-negative bacilli.
    DeMaria A; Treadwell TL; Saunders CA; Porat R; McCabe WR
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1137-43. PubMed ID: 2679368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aztreonam in the treatment of serious gram-negative infections in the elderly.
    Deger F; Douchamps J; Freschi E; Thys JP; Nève P; Herchuelz A
    Int J Clin Pharmacol Ther Toxicol; 1988 Jan; 26(1):22-6. PubMed ID: 3403089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of aztreonam in cancer patients.
    Jones PG; Bodey GP; Swabb EA; Ho DH; Fainstein V; Pasternak J
    Antimicrob Agents Chemother; 1984 Oct; 26(4):455-61. PubMed ID: 6542763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the clinical pharmacology of the monobactam antibiotic aztreonam.
    Swabb EA
    Am J Med; 1985 Feb; 78(2A):11-8. PubMed ID: 3881946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of single- and multiple-dose pharmacokinetics of the monobactam, aztreonam (SQ 26,776) in healthy subjects.
    Swabb EA; Sugerman AA
    Chemotherapy; 1983; 29(5):313-21. PubMed ID: 6684541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of aztreonam in healthy recipients and patients: a review.
    Swabb EA
    Rev Infect Dis; 1985; 7 Suppl 4():S605-12. PubMed ID: 3909317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of aztreonam in patients with chronic renal failure.
    Fillastre JP; Leroy A; Baudoin C; Humbert G; Swabb EA; Vertucci C; Godin M
    Clin Pharmacokinet; 1985; 10(1):91-100. PubMed ID: 4038635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of aztreonam and SQ 26,992 in elderly patients with renal insufficiency.
    Sattler FR; Schramm M; Swabb EA
    Rev Infect Dis; 1985; 7 Suppl 4():S622-7. PubMed ID: 4081474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of low dose aztreonam in the treatment of moderate to severe gram-negative bacterial infections.
    Clergeot A; Steru D; Rosset MA; Carbon C
    J Antimicrob Chemother; 1989 May; 23(5):753-8. PubMed ID: 2759924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
    Henry SA; Bendush CB
    Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
    Rabinad E; Bosch-Perez A
    Chemotherapy; 1989; 35 Suppl 1():1-7. PubMed ID: 2659288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A; Steru D; Rosset MA; Carbon C
    Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.